Fisher Asset Management LLC reduced its stake in Zimmer Biomet Holdings Inc (NYSE:ZBH) by 5.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 122,743 shares of the medical equipment provider’s stock after selling 7,512 shares during the period. Fisher Asset Management LLC’s holdings in Zimmer Biomet were worth $14,811,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Bank of Nova Scotia Trust Co. purchased a new stake in shares of Zimmer Biomet in the third quarter worth $112,000. FNY Managed Accounts LLC purchased a new stake in shares of Zimmer Biomet in the third quarter worth $117,000. BB&T Investment Services Inc. purchased a new stake in shares of Zimmer Biomet in the second quarter worth $144,000. Cerebellum GP LLC purchased a new stake in shares of Zimmer Biomet in the fourth quarter worth $133,000. Finally, Steward Partners Investment Advisory LLC purchased a new stake in shares of Zimmer Biomet in the third quarter worth $140,000. 85.91% of the stock is currently owned by hedge funds and other institutional investors.
Zimmer Biomet Holdings Inc (NYSE:ZBH) opened at $126.23 on Monday. Zimmer Biomet Holdings Inc has a 1-year low of $108.03 and a 1-year high of $133.49. The company has a debt-to-equity ratio of 0.88, a current ratio of 1.47 and a quick ratio of 0.78. The firm has a market capitalization of $25,560.00, a PE ratio of 39.32, a price-to-earnings-growth ratio of 1.94 and a beta of 1.15.
The company also recently announced a quarterly dividend, which will be paid on Monday, January 29th. Shareholders of record on Friday, December 29th will be issued a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a yield of 0.76%. The ex-dividend date is Thursday, December 28th. Zimmer Biomet’s dividend payout ratio is 29.91%.
ZBH has been the topic of a number of recent research reports. Deutsche Bank raised Zimmer Biomet from a “hold” rating to a “buy” rating and set a $128.00 target price on the stock in a research note on Tuesday, November 14th. Zacks Investment Research cut Zimmer Biomet from a “hold” rating to a “strong sell” rating in a research note on Monday, November 20th. Canaccord Genuity reissued a “hold” rating and issued a $125.00 target price on shares of Zimmer Biomet in a research note on Tuesday, December 19th. Goldman Sachs Group raised Zimmer Biomet from a “sell” rating to a “neutral” rating and set a $125.00 price target on the stock in a report on Tuesday, December 19th. Finally, Oppenheimer reaffirmed a “buy” rating on shares of Zimmer Biomet in a report on Tuesday, December 19th. Two analysts have rated the stock with a sell rating, five have assigned a hold rating, sixteen have issued a buy rating and one has given a strong buy rating to the company. Zimmer Biomet presently has a consensus rating of “Buy” and a consensus price target of $137.42.
ILLEGAL ACTIVITY NOTICE: This news story was posted by BBNS and is the sole property of of BBNS. If you are reading this news story on another publication, it was illegally copied and reposted in violation of U.S. and international copyright and trademark law. The legal version of this news story can be read at https://baseballnewssource.com/markets/fisher-asset-management-llc-sells-7512-shares-of-zimmer-biomet-holdings-inc-zbh/1873653.html.
About Zimmer Biomet
Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.
Want to see what other hedge funds are holding ZBH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zimmer Biomet Holdings Inc (NYSE:ZBH).
Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.